Drug Trial Radar · NCT00394953
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
Last checked: Nov 20, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
490
Actual
Start
Dec 2006
Primary completion
Nov 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Conditions
- Anemia
Interventions
Darbepoetin alfaDrug
As prescribed, iv.
methoxy polyethylene glycol-epoetin beta [Mircera]Drug
120, 200 or 360 micrograms iv / month, starting dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Lesser Than or Equal to One Gram Per Deciliter Decrease in Average Hemoglobin From Baseline and Maintaining Average Hemoglobin Level Greater Than or Equal to 10.5 g/dL Over Evaluation PeriodTime frame: Baseline (Week -4 to Week -1) and Evaluation period (Weeks 50 to 53)
Locations
88 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Adelaide, Australia
Site not named
Clayton, Australia
Site not named
Gosford, Australia
Site not named
Parkville, Australia
Site not named
Woolloongabba, Australia
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Aalst, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Roeselare, Belgium
Site not named
Calgary, Alberta, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Kitchener, Ontario, Canada
Site not named
Mississauga, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Greenfield Park, Quebec, Canada
Site not named
Trois-Rivières, Quebec, Canada
Site not named
Aalborg, Denmark
Site not named
Hillerød, Denmark
Site not named
Roskilde, Denmark
Site not named
Tampere, Finland
Site not named
Turku, Finland
Site not named
Auch, France
Site not named
Bordeaux, France
Site not named
Boulogne, France
Site not named
Castelnau-le-Lez, France
Site not named
Cergy-Pontoise, France
Site not named
Chamalières, France
Site not named
Dijon, France
Site not named
Fleury-Mérogis, France
Site not named
Hérouville-Saint-Clair, France
Site not named
La Tronche, France
Site not named
Lyon, France
Site not named
Montpellier, France
Site not named
Nîmes, France
Site not named
Paris, France
Site not named
Paris, France
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.